Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trialEnriqueta Felip, H. Wakelee, Alex Martínez‐Martí et al.|Annals of Oncology|2023Cited by 251
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockadeBarzin Y. Nabet, David S. Shames, Habib Hamidi et al.|Cancer Cell|2024Cited by 154